32460-07-4

Basic information

• Product Name: ethyl 3-bromofuran-2-carboxylate
• Synonyms: ethyl 3-bromofuran-2-carboxylate
• CAS NO: 32460-07-4
• Molecular Formula: C₇H₇BrO₃
• Molecular Weight: 219.03268
• EINECS: -0
• Mol File: 32460-07-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 3-bromofuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-bromofuran-2-carboxylate(32460-07-4)
• EPA Substance Registry System: ethyl 3-bromofuran-2-carboxylate(32460-07-4)

Safety Data

• Hazardous Substances Data: 32460-07-4(Hazardous Substances Data)

Upstream product

• 14903-90-3 3-bromofuran-2-carboxylic acid 
• 75-03-6 ethyl iodide 
• 14757-78-9 3-bromofurfural 
• 614-99-3 Ethyl 2-furoate 

Downstream Products

• 1357588-54-5 3-acetyl-1-[3-(trifluoromethyl)phenyl]furo[3,2-c]pyridazin-4(1H)-one 
• 1357588-51-2 3-(1-phenyl-1H-pyrazol-5-yl)-1-[3-(trifluoromethyl)phenyl]furo[3,2-c]pyridazin-4(1H)-one 
• 1357588-56-7 3-(1-hydroxyethyl)-1-[3-(trifluoromethyl)phenyl]-6,7-dihydrofuro[3,2-c]pyridazin-4(1H)-one 
• 1357588-57-8 3-acetyl-1-[3-(trifluoromethyl)phenyl]-6,7-dihydrofuro[3,2-c]pyridazin-4(1H)-one 
• 1357588-60-3 3-acetyl-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]furo[3,2-c]pyridazin-4(1H)-one 
• 1357588-58-9 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-3-(1-phenyl-1H-pyrazol-5-yl)furo[3,2-c]pyridazin-4(1H)-one 
• 1357588-61-4 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-3-(1-phenyl-1H-pyrazol-5-yl)-6,7-dihydrofuro[3,2-c]pyridazin-4(1H)-one 
• 1357588-62-5 3-(1-phenyl-1H-pyrazol-5-yl)-1-[4-(1H-pyrazol-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]furo[3,2-c]pyridazin-4(1H)-one 
• 1357588-63-6 3-(1-phenyl-1H-pyrazol-5-yl)-1-[4-(1H-pyrazol-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-6,7-dihydrofuro[3,2-c]pyridazin-4(1H)-one 
• 1622868-22-7 C₁₈H₂₂O₃ 
• 1622868-21-6 C₁₇H₂₀O₃ 
• 1622868-20-5 C₁₆H₁₈O₃ 
• 1622868-19-2 C₁₆H₁₈O₃ 
• 1622868-18-1 C₁₅H₁₆O₃ 

Relevant articles and documents

SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. A compound represented by the formula (1x): wherein each symbol is as des

Regio- and chemoselective C-H chlorination/bromination of electron-deficient arenes by weak coordination and study of relative directing-group abilities

It's all relative: A practical and efficient PdII-catalyzed regio- and chemoselective chlorination/bromination has been developed for the facile synthesis of a broad range of aromatic chlorides. The reaction demonstrates excellent reactivity, good functional-group tolerance, and high yields. A preliminary study was conducted to evaluate relative directing-group abilities of various functionalities. Copyright

2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula(I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent 0 or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.